U.S. Capital Wealth Advisors, LLC
Position in IKT — Inhibikase Therapeutics, Inc.
CIK 1808915
AUSTIN, TX
Position in IKT
as of Mar 31, 2026
· filed Apr 7, 2026
Position Value
$16,800
New position
Shares Held
10,000
first reported quarter
Ownership
0.007%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Mar 31, 2026U.S. Capital Wealth Advisors, LLC holds $11,669,198 across 6 Biotechnology names. IKT ranks #6 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
24,537 | $8,118,557 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
|
66,780 | $2,173,021 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,432 | $1,106,420 | |
| 4 | SMMT |
Summit Therapeutics Inc.
|
12,009 | $227,690 | |
| 5 | ALDX |
Aldeyra Therapeutics, Inc.
|
15,805 | $26,710 | |
| 6 | IKT |
Inhibikase Therapeutics, Inc.
This page
|
10,000 | $16,800 |
All Filings in IKT
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,800 | 10,000 | Shares | Sole | 2026-04-07 | |
| No filing history on record for this holder in this stock. | ||||||